Your browser doesn't support javascript.
Pulmonary Rehabilitation Accelerates the Recovery of Pulmonary Function in Patients With COVID-19.
Zhu, Pengfei; Wang, Zhengchao; Guo, Xiaomi; Feng, Zhiyong; Chen, Chaochao; Zheng, Ai; Gu, Haotian; Cai, Yu.
  • Zhu P; Department of Cardiology, Wuhan Fourth Hospital, Puai Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Wang Z; Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Guo X; Department of Ultrasound, Wuhan Asia General Hospital, Wuhan, China.
  • Feng Z; Department of Rehabilitation, Wuhan Fourth Hospital, Puai Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Chen C; Department of Rehabilitation, Wuhan Fourth Hospital, Puai Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Zheng A; Department of Rehabilitation, Wuhan Fourth Hospital, Puai Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Gu H; British Heart Foundation Centre of Research Excellence, King's College London, London, United Kingdom.
  • Cai Y; Department of Rehabilitation, Wuhan Fourth Hospital, Puai Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Front Cardiovasc Med ; 8: 691609, 2021.
Article in English | MEDLINE | ID: covidwho-1346399
ABSTRACT

Objectives:

To evaluate the effect of in-hospital pulmonary rehabilitation (PR) on short-term pulmonary functional recovery in patients with COVID-19.

Methods:

Patients with COVID-19 (n = 123) were divided into two groups (PR group or Control group) according to recipient of pulmonary rehabilitation. Six-min walk distance (6MW), heart rate (HR), forced vital capacity (FVC), forced expiratory volume in 1 s (FEV1), diffusing capacity of the lung for carbon monoxide (DLCO), and CT scanning were measured at the time of discharge, 1, 4, 12, and 24 weeks.

Results:

At week one, both PR group and Control group showed no significant changes in pulmonary function. At 4 and 12 weeks, 6MW, HR, FVC, FEV1, and DLCO improved significantly in both groups. However, the improvement in the PR group was greater than the Control group. Pulmonary function in the PR group returned to normal at 4 weeks [FVC (% predicted, PR vs. Control) 86.27 ± 9.14 vs. 78.87 ± 7.55; FEV1 (% predicted, PR vs. Control) 88.76 ± 6.22 vs. 78.96 ± 6.91; DLCO (% predicted, PR vs. Control) 87.27 ± 6.20 vs. 77.78 ± 5.85] compared to 12 weeks in the control group [FVC (% predicted, PR vs. Control) 90.61 ± 6.05 vs. 89.96 ± 4.05; FEV1 (% predicted, PR vs. Control) 94.06 ± 0.43 vs. 93.85 ± 5.61; DLCO (% predicted, PR vs. Control) 91.99 ± 8.73 vs. 88.57 ± 5.37]. Residual lesions on CT disappeared at week 4 in 49 patients in PR group and in 28 patients in control group (p = 0.0004).

Conclusion:

Pulmonary rehabilitation could accelerate the recovery of pulmonary function in patients with COVID-19.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Language: English Journal: Front Cardiovasc Med Year: 2021 Document Type: Article Affiliation country: Fcvm.2021.691609

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Language: English Journal: Front Cardiovasc Med Year: 2021 Document Type: Article Affiliation country: Fcvm.2021.691609